BCL2L12抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07040(BCL2L12 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P07040(BCL2L12 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The BCL2L12 (B-cell lymphoma 2-like 12) gene encodes a member of the BCL-2 protein family, which regulates apoptotic pathways by modulating mitochondrial membrane permeability and caspase activation. Discovered in 2002. BCL2L12 is unique among BCL-2 proteins due to its dual role in apoptosis, exhibiting both anti- and pro-apoptotic functions depending on cellular context, post-translational modifications, and interactions with other proteins. It is highly expressed in the brain, testes, and certain cancers, including glioblastoma, colorectal carcinoma, and breast cancer. In glioblastoma, BCL2L12 is associated with tumor aggressiveness and resistance to therapy, partly through its ability to inhibit caspase-7 and bind p53. thereby impairing apoptosis and promoting tumor survival.

BCL2L12 antibodies are critical tools for studying its expression, localization, and interactions in both physiological and pathological settings. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess protein levels in tissues or cell lines. Commercially available antibodies often target specific epitopes, such as the N-terminal or C-terminal regions, to ensure specificity. Researchers also utilize BCL2L12 antibodies to explore its potential as a diagnostic or prognostic biomarker in cancer, given its overexpression in malignancies and role in therapy resistance. However, antibody validation remains essential due to homology with other BCL-2 family members and splice variants. Understanding BCL2L12's complex biology through these reagents may inform therapeutic strategies targeting apoptotic dysregulation in cancer.